Free Trial

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Large Decrease in Short Interest

Ascentage Pharma Group International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest fell 49.8% to 9,125 shares as of October 30, equal to about 1.0 day of average trading volume; 0.0% of shares were reported short.
  • Analysts maintain a consensus Buy rating, with an average price target of $43.44. Recent targets range from $33 to $48, while JPMorgan cut its target from $46 to $33.
  • AAPG opened at $14.62, below its 50-day average of $15.36 and 200-day average of $19.61. In its latest reported quarter, the company posted an EPS loss of $0.65 and revenue of $22.24 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 9,125 shares, a decrease of 49.8% from the October 15th total of 18,161 shares. Based on an average trading volume of 8,875 shares, the short-interest ratio is presently 1.0 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

AAPG has been the subject of several analyst reports. Citigroup started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, October 14th. They issued a "buy" rating and a $46.00 price objective for the company. Citizens Jmp assumed coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, October 13th. They set a "market outperform" rating and a $35.00 target price on the stock. BTIG Research restated a "buy" rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. JPMorgan Chase & Co. lowered their target price on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an "overweight" rating on the stock in a report on Thursday, October 8th. Finally, William Blair started coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an "outperform" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $43.44.

Check Out Our Latest Research Report on AAPG

Ascentage Pharma Group International Price Performance

Shares of NASDAQ:AAPG opened at $14.62 on Monday. The firm has a 50 day moving average of $15.36 and a 200-day moving average of $19.61. Ascentage Pharma Group International has a 12 month low of $13.46 and a 12 month high of $34.50. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International will post -2.43 EPS for the current year.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company's two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ascentage Pharma Group International Right Now?

Before you consider Ascentage Pharma Group International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.

While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines